Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
Want to see TRIB full AI Analyst Report?
TRIB Stock Chart & Stats
$0.75
-$0.09(-10.05%)
At close: 4:00 PM EST
$0.75
-$0.09(-10.05%)
Day’s Range― - ―
52-Week Range$0.50 - $3.44
Previous CloseN/A
Volume141.89K
Average Volume (3M)136.14K
Market Cap
$11.11M
Enterprise Value$138.77M
Total Cash (Recent Filing)$5.14M
Total Debt (Recent Filing)$137.98M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding18,720,331
10 Day Avg. Volume159,092
30 Day Avg. Volume136,139
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.20
Price to Sales (P/S)0.33
P/FCF Ratio-2.32
Enterprise Value/Market Cap12.49
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit8.94
Enterprise Value/Ebitda-12.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$59.50M
Bulls Say, Bears Say
Bulls Say
IFCC Gold HbA1c CertificationEarning the sole IFCC Gold classification provides durable clinical credibility and differentiation in lab HbA1c testing. That accreditation supports payer confidence, easier laboratory adoption and upsell of recurring reagents, strengthening long-term installed-base driven revenue in a large diabetes diagnostics market.
CGM+ Technical ProgressMaterial accuracy improvements, needle-free insertion testing and multimodal electronics position CGM+ as a differentiated, AI‑native platform. Advancing to pivotal trials is a structural positive: a successful CGM product could create a high-growth recurring device/consumable revenue stream and a data moat for long-term services.
Approved Outsourced Uni‑Gold ManufacturingRegulatory signoff for offshore/outsourced Uni‑Gold production enables conversion of fixed costs to variable, scale manufacturing and lower unit costs. Structurally this improves margin sustainability and supports competitive pricing and volume growth in global HIV test procurement over the medium term.
Bears Say
Stressed Balance SheetPersistent negative equity and rising debt create ongoing solvency and refinancing risk, constraining strategic optionality. Over 2–6 months this fragility limits ability to invest in commercialization or R&D without dilutive financing or covenant relief and raises the chance of costly recapitalization.
Ongoing Cash BurnMulti-year negative operating and free cash flow means the company requires external funding to sustain operations and advance pivotal programs. This persistent cash burn increases dilution risk, pressures margins long term, and forces management to balance financing needs with commercialization investments.
Declining & Volatile RevenueMaterial revenue decline and quarter‑to‑quarter variability—driven by HIV funding shifts and manufacturing transitions—reduce predictability of margins and cash flow. This structural revenue volatility complicates scaling, makes forecasting and investment planning harder, and increases reliance on narrow product segments.
Trinity Biotech News
TRIB FAQ
What was Trinity Biotech Plc’s price range in the past 12 months?
Trinity Biotech Plc lowest stock price was $0.50 and its highest was $3.44 in the past 12 months.
What is Trinity Biotech Plc’s market cap?
Trinity Biotech Plc’s market cap is $11.11M.
When is Trinity Biotech Plc’s upcoming earnings report date?
Trinity Biotech Plc’s upcoming earnings report date is May 27, 2026 which is in 8 days.
How were Trinity Biotech Plc’s earnings last quarter?
Trinity Biotech Plc released its earnings results on Apr 08, 2026. The company reported -$0.938 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.938.
Is Trinity Biotech Plc overvalued?
According to Wall Street analysts Trinity Biotech Plc’s price is currently Overvalued.
Does Trinity Biotech Plc pay dividends?
Trinity Biotech Plc pays a Annually dividend of $1.1 which represents an annual dividend yield of N/A. See more information on Trinity Biotech Plc dividends here
What is Trinity Biotech Plc’s EPS estimate?
Trinity Biotech Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trinity Biotech Plc have?
Trinity Biotech Plc has 18,720,331 shares outstanding.
What happened to Trinity Biotech Plc’s price movement after its last earnings report?
Trinity Biotech Plc reported an EPS of -$0.938 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.165%.
Which hedge fund is a major shareholder of Trinity Biotech Plc?
Currently, no hedge funds are holding shares in TRIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Trinity Biotech Plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Technical Analysis
―
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.09% Mutual Funds
5.01% Other Institutional Investors
94.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---